About this trial
This longitudinal mechanistic physiological study examines biased β2-adrenergic receptor (β2-AR) signaling in human skeletal muscle, with emphasis on G protein-coupled receptor kinase (GRK)-mediated pathways. Participants will receive daily oral dosing of the GRK-selective long-acting β2-agonist ATR-258 for 8 weeks. Muscle biopsies and physiological measurements will quantify GRK-, cAMP/PKA-, and β-arrestin-related signaling, fiber-type specificity, and potential receptor desensitization with repeated stimulation.
Eligibility criteria
Qualifiers
Healthy men
Age 21-45 years
BMI 25-35 kg/m²
Body fat percentage 25-40%
Disqualifiers
Regular use of or allergy to β2-agonists
Serious adverse reactions to β2-agonists
Current smoker
Regular use of medication (except OTC allergy or analgesics)
Trial design
Treatments tested in this trial
- ATR-258
Treatment groups
Sponsors and collaborators
Morten Hostrup, PhD
Lead sponsor
University of Copenhagen
Sponsor institution
Atrogi AB
Collaborator
University of Copenhagen
Collaborator
Stockholm University
Collaborator